The Chief Executive of German biotechnology company IDT Biologika, Juergen Betzing, said the company plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year, Reuters news agency reported on Monday.
IDT Biologika is a German contract development and manufacturing company focussed on the development and manufacture of live viral vaccines.
Betzing was quoted as saying at a news conference that the company hopes to be able to apply for approval in 2021.
"If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021," Betzing added.
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications
Sanofi increases Sanofi Ventures funding by USD625m to boost biotech and digital health investments
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
AusperBio completes patient enrolment in two Phase II clinical trials of AHB-137
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication